Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Resmed Inc banner

Resmed Inc
F:RME

Watchlist Manager
Resmed Inc Logo
Resmed Inc
F:RME
Watchlist
Price: 194 EUR 0.83% Market Closed
Market Cap: €28.5B
Write Note Create Alert Ask AI

Wall St Price Targets

RME Price Forecast
Based on 21 analysts

+29% Upside
from €194 today

RME Analyst Rating
No ratings yet

No rating

We don't have analyst ratings for RME yet.

Resmed Inc Competitors:
Price Targets

Revenue
Forecast

11% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
11% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 14 years, the compound annual growth rate for Revenue has been 11%. The projected CAGR for the next 3 years is 6%.

What are analyst estimates?

Gross Profit
Forecast

11% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
11% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 14 years, the compound annual growth rate for Gross Profit has been 11%. The projected CAGR for the next 3 years is 7%.

What are analyst estimates?

Operating Income
Forecast

14% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
14% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Over the last 14 years, the compound annual growth rate for Operating Income has been 14%. The projected CAGR for the next 3 years is 8%.

What are analyst estimates?

Pre-Tax Income
Forecast

13% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss
13% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 13%. The projected CAGR for the next 3 years is 9%.

What are analyst estimates?

Net Income
Forecast

14% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
14% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Over the last 14 years, the compound annual growth rate for Net Income has been 14%. The projected CAGR for the next 3 years is 9%.

What are analyst estimates?

Continue RME Research

Summary
RME intrinsic value, competitors valuation, and company profile.
DCF Valuation
RME stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RME stock valuation using valuation multiples.
Wall St Estimates
RME price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RME stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Resmed Inc listings:
NYSE • USD
RMD
 LSE • USD
0KW4
 ASX • AUD
RMD
 F • EUR
RMEA
 OTC • USD
RSMDF
 XMUN • EUR
RME
 SWB • EUR
RME
 SWB • EUR
RMEA
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is RME's stock price target?
Price Target
250.5 EUR

According to Wall Street analysts, the average 1-year price target for RME is 250.5 EUR with a low forecast of 184.71 EUR and a high forecast of 351.13 EUR.

What is the Revenue forecast for Resmed Inc?
Projected CAGR
6%

Over the last 14 years, the compound annual growth rate for Revenue has been 11%. The projected CAGR for the next 3 years is 6%.

What is the Gross Profit forecast for Resmed Inc?
Projected CAGR
7%

Over the last 14 years, the compound annual growth rate for Gross Profit has been 11%. The projected CAGR for the next 3 years is 7%.

What is the Operating Income forecast for Resmed Inc?
Projected CAGR
8%

Over the last 14 years, the compound annual growth rate for Operating Income has been 14%. The projected CAGR for the next 3 years is 8%.

What is the Pre-Tax Income forecast for Resmed Inc?
Projected CAGR
9%

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 13%. The projected CAGR for the next 3 years is 9%.

What is the Net Income forecast for Resmed Inc?
Projected CAGR
9%

Over the last 14 years, the compound annual growth rate for Net Income has been 14%. The projected CAGR for the next 3 years is 9%.

Back to Top
ALPHA SPREAD
Follow us
Join 359,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.